Suppr超能文献

多巴胺再摄取抑制剂对大鼠脑内透析法测定的体内多巴胺释放的影响并不一致。

Dopamine re-uptake inhibitors show inconsistent effects on the in vivo release of dopamine as measured by intracerebral dialysis in the rat.

作者信息

Westerink B H, Damsma G, De Vries J B, Koning H

出版信息

Eur J Pharmacol. 1987 Mar 17;135(2):123-8. doi: 10.1016/0014-2999(87)90603-0.

Abstract

The effects of the dopamine (DA) re-uptake blockers amfonelic acid and GBR 12909 on the in vivo release of DA were investigated. DA release was measured by means of a fully automated brain dialysis system. GBR 12909 induced a 3-fold increase in the output of DA; amfonelic acid was without effect. These results indicate a dissociation between the behavioural effects of DA re-uptake blockers and the effects on DA release. A strong synergistic rise of DA release was observed when haloperidol was co-administered with amfonelic acid or GBR 12909. The potentiation of DA release was completely prevented by infusion of 1 microM tetrodotoxin.

摘要

研究了多巴胺(DA)再摄取阻滞剂安非那酸和GBR 12909对DA体内释放的影响。采用全自动脑透析系统测量DA释放。GBR 12909使DA输出增加了3倍;安非那酸则无此作用。这些结果表明DA再摄取阻滞剂的行为效应与对DA释放的效应之间存在分离。当氟哌啶醇与安非那酸或GBR 12909联合给药时,观察到DA释放有强烈的协同增加。输注1微摩尔河豚毒素可完全阻止DA释放的增强。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验